ESMO Congress 2026

Every phase 3 readout in the perioperative treatment of muscle-invasive bladder cancer (MIBC) now unfolds against a systematically quantified disease-burden backdrop: GBD 2017 estimated incidence, prevalence, and years lived with disability for 354 diseases and injuries across 195 countries and territories ^[1], and assessed mortality within a framework of 282 causes of death by country ^[2]. This baseline means any rewriting of the MIBC treatment pathway will be weighed on a global public-health scale ^[1][2]. As for the specific direction of perioperative immunotherapy, the reference point repeatedly invoked by peers at this meeting is the NIAGARA study, whose detailed design and data are not disclosed in the current materials.

In the GU oral session at ESMO26, Jens Bedke presented KN-866: a phase 3 study of perioperative cisplatin-gemcitabine (CisGem) plus pembrolizumab versus CisGem alone in MIBC, which was a negative study — no benefit in EFS or OS, with only a slight increase in pCR. A second readout was discussed side by side: ENERGIZE, which evaluated perioperative CisGem with or without nivolumab in MIBC and likewise showed no improvement in survival endpoints; the poster called it "just like KN-866" and "food for thought."

Taken together, the two negative readouts move the field's understanding forward one step: adding a PD-1 inhibitor on top of full perioperative CisGem chemotherapy — pembrolizumab in one case, nivolumab in the other — did not translate into survival gains, leaving only a slight rise in pCR, in sharp contrast to NIAGARA. Attendees immediately posed the question: which could be the reasons that explain these discordant results? This suggests that success in perioperative immunotherapy may hinge on regimen structure and timing rather than being extrapolated straightforwardly within the same tumor type.

The limitations are equally clear: the posts offer only directional conclusions, with HRs, P values, sample sizes, and follow-up durations not disclosed; the specific numbers of NIAGARA remain to be confirmed; and ENERGIZE's pCR performance is not mentioned in the posts. Until the full datasets are released, these cross-trial comparisons can only remain qualitative.